ARA-290 (Cibinetide): Research, Dosing, and Safety
This is a research-first profile of ARA-290 (Cibinetide), also indexed as Arra 290. It aggregates mechanism notes, transcript dosing mentions, vendor recommendations, and PubMed-indexed literature, and it does not present medical guidance.
ARA-290 (Cibinetide) is a research compound profiled here from named-expert transcripts and peer-reviewed literature, without medical guidance. As of July 2026, The Peptide Wiki aggregates 8 PubMed-cited papers and 1 transcript dosing protocol for ARA-290 (Cibinetide), each linked to its source.
- Also indexed as Arra 290.
- 1 aggregated dosing-protocol mention from source transcripts.
- 8 PubMed-indexed citations listed in the research table below.
- 0 vendor recommendations captured from named experts.
What is ARA-290 (Cibinetide)?
ARA-290 (Cibinetide), also indexed as Arra 290, is a research compound aggregated here from creator transcripts and PubMed-indexed literature. This page collects existing mentions and makes no direct disease-treatment claims.
ARA-290 (Cibinetide) Dosing Protocols
The table below lists transcript-derived dosing mentions for ARA-290 (Cibinetide). Entries are preserved for research context and are not medical advice.
| Speaker | Source | Timestamp | Protocol | Evidence |
|---|---|---|---|---|
| Hunter | Saturday Morning Coffee Talk 6/6/26 | 01:06:44 | Hunter reports starting at 1 mg. The transcript notes that clinical trials evaluated 4 mg daily for 30 days in neuropathy studies. Anecdotal reports indicate that users have experimented with 1-2 mg/day protocols. | anecdotal |
Vendor Recommendations for ARA-290 (Cibinetide)
No tracked vendor recommendations for ARA-290 (Cibinetide) yet. See our vendor directory.
Side Effects and Safety
Anecdotal reports and study-level observations vary by route, dose, and individual. This page does not provide medical advice. Consult a qualified clinician before any research use.
User Reviews
A user reviews aggregator is coming in Q3 2026, drawing on Reddit, YouTube comments, and Discord research notes. Until then, see the expert quote section above and the PubMed citations below.
Research Efficacy Snapshot
This section collects published efficacy figures cited in PubMed trials and named-expert reports about ARA-290 (Cibinetide). Each line links to the original source.
- "One month of CIB treatment significantly increased the cortical (~5.8%) and trabecular (~5.2%) bone mineral density in C57BL/6J WT female mice." · Awida Z et al, 2021 PubMed
- "Similarly, administration of CIB for five consecutive days to female mice that concurrently received EPO on days one and four, reduced the number of osteoclast progenitors, defined by flow cytometry as Lin-CD11b-Ly6Chi CD115+, by 42.8% compared to treatment with EPO alone." · Awida Z et al, 2021 PubMed
- "Diabetic neuropathy is a multifaceted condition affecting up to 50% of individuals with long standing diabetes." · Rendell M et al, 2021 PubMed
- "The placebo-corrected mean change from baseline CNFA (μm2) at day 28 was 109 (95% confidence interval [CI], -429, 647), 697 (159, 1236; P = 0.012), and 431 (-130, 992) in the 1, 4, and 8 mg groups, respectively." · Culver D et al, 2017 PubMed
Research and Studies
8 PubMed-indexed papers reference ARA-290 (Cibinetide). All 8 are listed below.
Legal Status
ARA-290 (Cibinetide) is presented here as a research compound. FDA approval status, scheduling, WADA status, and state-specific telehealth rules may apply. Always verify current regulatory status. Last verified: 2026-07-03.
Frequently Asked Questions
Is ARA-290 (Cibinetide) FDA-approved?
ARA-290 (Cibinetide) is presented on this page as a research compound. FDA approval status, scheduling, and state-specific rules may apply and change. Verify current regulatory status before any decision.
What dosing is reported for ARA-290 (Cibinetide)?
This page aggregates 1 dosing-protocol mention from named-expert transcripts, each linked to a verbatim source timestamp. See the Dosing Protocols table above. Mentions are anecdotal, not medical advice.
How much research has been published on ARA-290 (Cibinetide)?
8 PubMed-indexed papers reference ARA-290 (Cibinetide) in our current research feed. See the Research and Studies section above for citations.